Stock Traders Buy Large Volume of Illumina Call Options (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) was the target of some unusual options trading on Tuesday. Traders bought 15,326 call options on the company. This is an increase of approximately 597% compared to the typical volume of 2,198 call options.

Illumina Trading Up 1.4%

NASDAQ ILMN traded up $1.76 during trading hours on Tuesday, hitting $123.48. 1,508,068 shares of the company’s stock were exchanged, compared to its average volume of 2,174,599. The firm has a market cap of $18.87 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 2.34 and a beta of 1.42. The stock has a 50-day simple moving average of $100.95 and a 200 day simple moving average of $94.88. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina has a 1-year low of $68.70 and a 1-year high of $153.06.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the business earned $1.14 EPS. The company’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by corporate insiders.

Institutional Trading of Illumina

Several large investors have recently made changes to their positions in ILMN. Parkside Financial Bank & Trust grew its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the period. Quent Capital LLC acquired a new position in Illumina during the third quarter worth $29,000. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. bought a new position in Illumina in the 2nd quarter valued at about $41,000. Finally, NewSquare Capital LLC boosted its stake in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ILMN shares. Royal Bank Of Canada set a $124.00 price target on Illumina in a research note on Tuesday, September 2nd. Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a report on Tuesday, August 12th. Robert W. Baird set a $109.00 price target on shares of Illumina in a research note on Friday, October 31st. Finally, Evercore ISI lifted their price target on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.